share_log

Virpax Pharmaceuticals | DEF 14A: Definitive information statements

Virpax Pharmaceuticals | DEF 14A: Definitive information statements

Virpax制药 | DEF 14A：股东委托书决议
美股SEC公告 ·  06/12 17:13

Moomoo AI 已提取核心信息

Virpax Pharmaceuticals, Inc. (Virpax) has announced several key proposals to be voted on at their upcoming Annual Meeting of Stockholders scheduled for July 29, 2024. The proposals include the ratification of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and amendments to the 2022 Equity Incentive Plan. The amendments aim to increase the number of shares authorized for issuance under the plan by 267,799 shares to a total of 500,000 shares and to raise the 'evergreen provision' percentage from 2% to 5% of the outstanding shares of Common Stock at year-end. Additionally, the meeting will address the election of two Class III directors to the Board, the ratification of the appointment of EisnerAmper LLP, approval of amendments to the 2022 Equity Incentive Plan, and if necessary, approval of adjournment of the meeting to allow for further solicitation of proxies if there are not sufficient votes in favor of the plan amendments. The Board of Directors has recommended approval for each of these proposals.
Virpax Pharmaceuticals, Inc. (Virpax) has announced several key proposals to be voted on at their upcoming Annual Meeting of Stockholders scheduled for July 29, 2024. The proposals include the ratification of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and amendments to the 2022 Equity Incentive Plan. The amendments aim to increase the number of shares authorized for issuance under the plan by 267,799 shares to a total of 500,000 shares and to raise the 'evergreen provision' percentage from 2% to 5% of the outstanding shares of Common Stock at year-end. Additionally, the meeting will address the election of two Class III directors to the Board, the ratification of the appointment of EisnerAmper LLP, approval of amendments to the 2022 Equity Incentive Plan, and if necessary, approval of adjournment of the meeting to allow for further solicitation of proxies if there are not sufficient votes in favor of the plan amendments. The Board of Directors has recommended approval for each of these proposals.
Virpax药品公司宣布，2024年7月29日召开的股东年会上将投票表决多项关键提案。包括批准EisnerAmper LLP为截止2024年12月31日的独立注册公共会计师事务所，以及修改2022年股权激励计划。针对修改的提案旨在将该计划授权发行的股票数量增加267,799股，总数达到500,000股，并将“常青条款”的百分比从年末的普通股总数2%提高到5%。此外，此次会议还将讨论选举两名董事会三类董事，批准EisnerAmper LLP的任命，批准修改2022年股权激励计划并审批再次延期会议的提案，以便进一步调动代理人，如果投票赞成计划修订的人数不足。董事会推荐批准这些提案。
Virpax药品公司宣布，2024年7月29日召开的股东年会上将投票表决多项关键提案。包括批准EisnerAmper LLP为截止2024年12月31日的独立注册公共会计师事务所，以及修改2022年股权激励计划。针对修改的提案旨在将该计划授权发行的股票数量增加267,799股，总数达到500,000股，并将“常青条款”的百分比从年末的普通股总数2%提高到5%。此外，此次会议还将讨论选举两名董事会三类董事，批准EisnerAmper LLP的任命，批准修改2022年股权激励计划并审批再次延期会议的提案，以便进一步调动代理人，如果投票赞成计划修订的人数不足。董事会推荐批准这些提案。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间